Wright R O, Lewander W J, Woolf A D
Department of Pediatrics, Division of Emergency Medicine, Hasbro Children's Hospital, Brown Medical School, Rhode Island Poison Control Center, Providence, RI 02903, USA.
Ann Emerg Med. 1999 Nov;34(5):646-56. doi: 10.1016/s0196-0644(99)70167-8.
Methemoglobin (MHb) may arise from a variety of etiologies including genetic, dietary, idiopathic, and toxicologic sources. Symptoms vary from mild headache to coma/death and may not correlate with measured MHb concentrations. Toxin-induced MHb may be complicated by the drug's effect on other organ systems such as the liver or lungs. The existence of underlying heart, lung, or blood disease may exacerbate the toxicity of MHb. The diagnosis may be complicated by the effect of MHb on arterial blood gas and pulse oximeter oxygen saturation results. In addition, other dyshemoglobins may be confused with MHb. Treatment with methylene blue can be complicated by the presence of underlying enzyme deficiencies, including glucose-6-phosphate dehydrogenase deficiency. Experimental antidotes for MHb may provide alternative treatments in the future, but require further study.
高铁血红蛋白(MHb)可能由多种病因引起,包括遗传、饮食、特发性和毒理学来源。症状从轻度头痛到昏迷/死亡不等,可能与测得的MHb浓度无关。毒素诱导的MHb可能因药物对其他器官系统(如肝脏或肺部)的影响而变得复杂。潜在的心脏、肺部或血液疾病的存在可能会加重MHb的毒性。MHb对动脉血气和脉搏血氧饱和度结果的影响可能会使诊断变得复杂。此外,其他异常血红蛋白可能会与MHb混淆。亚甲蓝治疗可能因存在潜在的酶缺乏症(包括葡萄糖-6-磷酸脱氢酶缺乏症)而变得复杂。MHb的实验性解毒剂未来可能会提供替代治疗方法,但需要进一步研究。